Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

BTIG starts Axcella Health at buy; PT $10

BTIG launched coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $10 price target. The stock closed at $4.66 on April 30. “We view Axcella’s calculated approach to correcting metabolic diseases with...

May 1, 2020

Markets

BTIG starts Mersana Therapeutics at buy; PT $14

BTIG launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with a “buy” rating and $14 price target. The stock closed at $9.36 on April 28. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer...

April 29, 2020

Markets

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

H.C. Wainwright more than doubled the price target for Arcturus Therapeutics (NASDAQ:ARCT) to $62 from $26, citing impressive preclinical results from its COVID-19 vaccine candidate. Shares of Arcturus jumped $7.96, to...

April 28, 2020

Markets

SVB Leerink starts Zentalis Pharma at OP; PT $45

SVB Leerink initiated coverage of Zentalis Pharmaceuticals (NASDAQ:ZNTL) with an “outperform” rating and $45 price target. The stock closed at $31.76 on April 27. Zentalis’ lead compound is an oral selective estrogen...

April 28, 2020

Markets

Ladenburg ups Avadel Pharma PT to $20 from $14

Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $20 from $14 after the company posted positive topline Phase 3 results for FT218, a once nightly formulation of Micropump controlled...

April 28, 2020

Markets

Ladenburg starts Salarius Pharma at buy; PT $3.80

Ladenburg Thalmann launched coverage of Salarius Pharmaceuticals (NASDAQ:SLRX) with a “buy” rating and price target of $3.80. The stock closed at 63 cents on April 24. Salarius obtained a NASDAQ listing through a...

April 27, 2020

Markets

SVB Leerink cuts Clovis Oncology to underperform; PT to $5 from $10

SVB Leerink downgraded Clovis Oncology (NASDAQ:CLVS) to “underperform” from “market perform” and halved its price target to $5 from $10, citing a fading opportunity in prostate cancer and escalating cash constraints...

April 27, 2020

Markets

BTIG ups Centogene PT to $23 from $18

BTIG raised its price target for Centogene (NASDAQ:CNTG) to $23 from $18, citing a “solid execution” in its pharma and diagnostics segments in 2019. The stock closed at $18.69 on April 23. Analyst Sung Ji Nam writes...

April 24, 2020

Markets

Stifel starts Radius Health at hold; PT $20

Stifel initiated coverage of Radius Health (NASDAQ:RDUS) with a “hold” rating and $20 target price. The stock closed at $17.18, up $1.43, on April 23. Analyst Annabel Samimy writes that Radius established a solid...

April 24, 2020

Markets

AGP cuts Interpace Biosciences PT to $9.25

Alliance Global Partners lowered its price target for Interpace Biosciences (NASDAQ:IDXG) to $9.25 from a reverse split-adjusted $21, but maintained its “buy” rating, after the company posted fourth quarter...

April 24, 2020

Markets

Piper starts Cutera at OW; PT $18

Piper Sandler launched coverage of Cutera (NASDAQ:CUTR) with an “overweight” rating and $18 price target. The stock closed at $11.36 on April 21. Cutera is an aesthetics provider with technologies that will perform a...

April 22, 2020

Markets

HCW starts Bicycle Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $25 price target. The stock finished at $14.66 on April 17. The company is focused on bicycles, which are synthetic, short...

April 20, 2020

Markets

Mackie cuts Medicure PT to $2.80 from $6.50

Mackie Research slashed its price target for Medicure (TSXV:MPH) to $2.80 from $6.50, and maintained a “hold” rating, citing highly lowered revenue estimates. The stock closed at $2.41 on April 15. Analyst Andre Uddin...

April 16, 2020

Markets

BTIG ups Arcus Biosciences PT to $34 from $20

BTIG raised its price target for Arcus Biosciences (NYSE:RCUS) to $34 from $20, citing investors meetings with Arcus management that “reinforced careful development of important assets.” The stock closed at $15.58 on...

April 16, 2020

Markets

Janney starts Interpace Biosciences at buy; fair value estimate $12

Janney Montgomery Scott launched coverage of Interpace Biosciences (NASDAQ:IDXG) with a “buy” rating and fair value estimate of $12. The stock closed at $4.81 on April 14. Analyst Paul Knight writes that Interpace has...

April 15, 2020

Markets

Canaccord ups Vapotherm PT to $20 from $14

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $20 from $14, citing preannounced first quarter results that beat expectations. The stock closed at $16.65 on April 13. Vapotherm is focused on the...

April 14, 2020

Markets

Roth starts Stealth BioTherapeutics at buy; PT $9

Roth Capital Partners launched coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and $9 price target. The stock closed at $1.59 on April 13. Stealth is focused on developing drugs targeted for rare...

April 14, 2020

Markets

Brookline starts Bellerophon Therapeutics at buy; PT $35

Brookline Capital Markets initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $35 price target. The stock closed at $11.91 on April 13. Bellerophon is developing inhaled nitric oxide...

April 14, 2020

Markets

HCW cuts Entasis Therapeutics PT to $5 from $18 on dilution

H.C. Wainwright slashed its price target for Entasis Therapeutics (NASDAQ:ETTX) to $5 from $18, but maintained its “buy” rating, citing a major financing that carries substantial dilution. The stock closed at $2.64 on...

April 14, 2020

Markets

Cowen starts Stereotaxis at OP; PT $6

Cowen launched coverage of Stereotaxis (NYSE American:STXS) with an “outperform” rating and $6 price target. The stock closed at $2.71 on April 8. Genesis is Stereotaxis’ next-generation robotic magnetic navigation...

April 9, 2020

Markets

Analysts cuts Neuronetics PTs citing COVID-19 impact

Analysts for BTIG and Canaccord Genuity slashed their price target for Neuronetics (NASDAQ:STIM) but maintained their “buy” ratings, citing a potential leaner post-pandemic business model. Neuronetics markets the...

April 9, 2020

Markets

Stifel starts Cue Biopharma at buy; PT $21

Stifel initiated coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $21 price target. The stock closed at $16.60, up $1.53, on April 8. “We believe the Immuno-STAT platform from which the company’ wholly...

April 9, 2020

Subscribe